A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/08/2011	WO2011152807A1 Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid
12/08/2011	WO2011152806A1 Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate
12/08/2011	WO2011152803A1 Water soluble formulation comprising a combination of amlodipine and a statin
12/08/2011	WO2011152755A1 Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system
12/08/2011	WO2011152751A1 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone-based composition and method for the production thereof
12/08/2011	WO2011152730A2 Stable high lipid liquid formula
12/08/2011	WO2011152721A1 Derivatives of pantothenic acid and their use for the treatment of malaria
12/08/2011	WO2011152720A1 Pantothenic acid derivatives and their use in the treatment of microbial infections
12/08/2011	WO2011152671A2 Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin
12/08/2011	WO2011152657A2 Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
12/08/2011	WO2011152652A2 Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day
12/08/2011	WO2011152516A1 Anti-tumor agent combined with kinase inhibitor
12/08/2011	WO2011152515A1 Antitumor agent containing indole compound
12/08/2011	WO2011152508A1 Optically active dibenzylamine derivative, and manufacturing method for same
12/08/2011	WO2011152485A1 Novel 4,5-fused pyrimidine derivative
12/08/2011	WO2011152411A1 Crystal of thienopyrimidine derivative
12/08/2011	WO2011152351A1 Purinone derivative
12/08/2011	WO2011152297A1 Solid dispersion comprising triazole compound
12/08/2011	WO2011152155A1 Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-γ-lactone precursor
12/08/2011	WO2011152071A1 Novel hyaluronic acid decomposition-promoting factor and inhibitor thereof
12/08/2011	WO2011152007A1 Sympathetic nerve depressant, skin temperature reducing agent, and cosmetic composition, food, and sundry items containing said depressant or agent
12/08/2011	WO2011152005A1 Sympatholytic agent, and cosmetic, food and sundry containing same
12/08/2011	WO2011151978A1 Fluorescent dye material and use thereof
12/08/2011	WO2011151835A1 A novel synergistic pharmaceutical composition for topical applications
12/08/2011	WO2011151832A1 Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof
12/08/2011	WO2011151824A1 Novel pharmaceutical compounds
12/08/2011	WO2011151822A1 3-substituted vinylboronates and uses thereof
12/08/2011	WO2011151808A1 Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
12/08/2011	WO2011151807A1 Conjugates for the prevention or treatment of nicotine addiction
12/08/2011	WO2011151782A1 A role for somatostatin to modulate initiation of follicular growth in the human ovary
12/08/2011	WO2011151731A2 Surgical adjuvant composition and associated methods of use
12/08/2011	WO2011151708A1 Gastroretentive dosage forms of gaba analogs
12/08/2011	WO2011151701A1 6 - methyl - 4 - phenyl - 5 - ( phenyl or cycloalkyl) carbamoyl - 1,2,3, 4 - tetrahydropyrimidin- 2 - one derivatives as antitubercular agents
12/08/2011	WO2011151685A1 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
12/08/2011	WO2011151667A1 Antiviral compositions
12/08/2011	WO2011151652A1 Benzodiazepine compounds useful for the treatment of hepatitis c
12/08/2011	WO2011151651A1 Benzodiazepine compounds useful for the treatment of hepatitis c
12/08/2011	WO2011151640A1 Processes for the preparation of dipyridamole
12/08/2011	WO2011151621A1 Compounds for the treatment of clostridium difficile associated disease
12/08/2011	WO2011151620A1 Compounds for the treatment of clostridium difficile associated disease
12/08/2011	WO2011151619A1 Compounds for the treatment of clostridium difficile associated disease
12/08/2011	WO2011151617A1 Compounds for the treatment of clostridium difficile associated disease
12/08/2011	WO2011151499A1 Use of an iminosugar as an inhibitor of epithelial cell adhesion
12/08/2011	WO2011151493A1 Sp2 iminosugar derivatives as alfa-glycosidase inhibitors
12/08/2011	WO2011151461A2 Autotaxin pathway modulation and uses thereof
12/08/2011	WO2011151436A2 Novel compounds, method for use them and pharmaceutical composition containing them
12/08/2011	WO2011151434A1 Novel compounds, pharmaceutical composition and methods for use in treating metabolic disorders
12/08/2011	WO2011151423A1 Substituted isoquinolines and their use as tubulin polymerization inhibitors
12/08/2011	WO2011151399A1 Rhenium complexes and their pharmaceutical use.
12/08/2011	WO2011151395A2 Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
12/08/2011	WO2011151372A1 Treatment of rheumatoid arthritis with masitinib
12/08/2011	WO2011151362A1 Nitrate and diazeniumdiolate derivatives of pioglitazone
12/08/2011	WO2011151361A1 Novel compounds
12/08/2011	WO2011151360A1 Aminopyrimidine derivatives as lrrk2 modulators
12/08/2011	WO2011151359A1 Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
12/08/2011	WO2011151358A1 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
12/08/2011	WO2011151357A1 Inhibitors of jnk
12/08/2011	WO2011151330A1 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
12/08/2011	WO2011151320A1 Nitroimidazole derivatives
12/08/2011	WO2011151287A1 Naphthocyanines for use as contrast agents
12/08/2011	WO2011151285A1 New compounds for the prevention and/or treatment of osteoarthrosis
12/08/2011	WO2011151259A1 Substituted imidazopyrazines
12/08/2011	WO2011151251A1 New ccr2 antagonists
12/08/2011	WO2011151088A1 Use of orlistat for the anti-parasitic treatment of a parasitic disease
12/08/2011	WO2011151087A1 Oral dosage forms of bendamustine
12/08/2011	WO2011151086A1 Oral dosage forms of bendamustine and therapeutic use thereof
12/08/2011	WO2011151080A1 Pharmaceutical compositions of co-crystals of tramadol and coxibs
12/08/2011	WO2011150960A1 Formulation comprising nicotine and a cation exchange resin
12/08/2011	WO2011150959A1 Formulation comprising nicotine and a cation exchange resin
12/08/2011	WO2011150939A1 Polymorphs of 2'-o-fucosyllactose and producing thereof
12/08/2011	WO2011150859A1 Oral meclizine aqueous formulations with taste flavoring agent
12/08/2011	WO2011150855A1 Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
12/08/2011	WO2011150682A1 4-hydroxyquinoline-3-amide derivatives and preparation methods and uses thereof
12/08/2011	WO2011150679A1 Crystalline form of carbapenem derivative or its hydrates and preparation methods and uses thereof
12/08/2011	WO2011150566A1 Novel dna vaccine adjuvant
12/08/2011	WO2011150505A1 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
12/08/2011	WO2011150493A1 Mitochondrial penetrating peptides as carriers for antimicrobials
12/08/2011	WO2011150481A1 Nanoparticulate composition containing antibiotics for intramammary administration in animals
12/08/2011	WO2011150453A1 Diagnostic, prognostic and therapeutic use of a long non-coding rna
12/08/2011	WO2011150441A1 Medical aerosol formulation comprising ribavirin
12/08/2011	WO2011128910A3 A drug delivery solid dosage formulation of sirolimus
12/08/2011	WO2011125070A3 Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
12/08/2011	WO2011123946A8 Kinase inhibitors and method of treating cancer with same
12/08/2011	WO2011121453A3 Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
12/08/2011	WO2011121357A3 Transcription factor decoys
12/08/2011	WO2011115599A3 Orally disintegrating tablet formulations of donepezil and process for preparing the same
12/08/2011	WO2011113895A3 Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase iv (dp iv)
12/08/2011	WO2011103599A9 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
12/08/2011	WO2011103028A3 Compositions and methods for inhibiting mmset
12/08/2011	WO2011102695A9 Composition for preventing or treating diseases caused by over-expression of lxrα, containing liquiritigenin or isoliquiritigenin as active ingredient
12/08/2011	WO2011098689A3 Use of agomelatine for the preparation of drugs for treating obsessive compulsive disorder (ocd)
12/08/2011	WO2011097617A3 Compositions and methods for reducing appearance of under-eye dark circles
12/08/2011	WO2011097456A3 Compositions and methods for enhanced parvovirus transduction
12/08/2011	WO2011085066A3 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
12/08/2011	WO2011076421A3 Compositions comprising venlafaxine and celecoxib in the treatment of pain
12/08/2011	WO2011076420A3 Co-crystals of venlafaxine and celecoxib
12/08/2011	WO2011072275A3 Agents and methods for treating ischemic and other diseases
12/08/2011	WO2011058351A3 Pharmaceutical composition
12/08/2011	WO2011042902A3 Microcapsules comprising benzoyl peroxide and topical compositions comprising them
12/08/2011	WO2011015744A3 Injectable composition combining a filling agent and a fibroblast growth medium

1 ... 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 ... 7860